✦ LIBER ✦

BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

✍ Scribed by Press, Richard D.; Kamel-Reid, Suzanne; Ang, Daphne

Book ID: 122448481
Publisher: American Society for Investigative Pathology
Year: 2013
Tongue: English
Weight: 720 KB
Volume: 15
Category: Article
ISSN: 1525-1578
DOI: 10.1016/j.jmoldx.2013.04.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Importance of adherence to BCR-ABL tyros

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia

✍ de Almeida, Maria Helena; Fogliatto, Laura; Couto, Dulce 📂 Article 📅 2014 🏛 SciELO 🌐 English ⚖ 170 KB

Molecular monitoring in chronic myeloid

Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications

✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation

Efficacy and Safety of a Specific Inhibi

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

✍ Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabe 📂 Article 📅 2001 🏛 Massachusetts Medical Society 🌐 English ⚖ 177 KB

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Stem cell transplantation for patients w

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I

✍ Nikolai Velev; Jorge Cortes; Richard Champlin; Dan Jones; Gabriela Rondon; Sergi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera